임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
50건 표시
- 3상모집 중· Non-small Cell Lung CancerA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
리드: 머크(MSD)
- 3상모집 중· Non-small Cell Lung CancerA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
리드: 머크(MSD) · 협력: 모더나
- 3상모집 중· Bladder CancerA Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
리드: 머크(MSD)
- 3상모집 중· Carcinoma, Renal CellA Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
리드: 머크(MSD)
- 3상모집 중· Von Hippel-Lindau DiseaseExtension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
리드: 머크(MSD)
- 3상모집 중· Non-small Cell Lung CancerMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
리드: 머크(MSD)
- 3상모집 중· Ovarian NeoplasmsA Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
리드: 머크(MSD)
- 3상모집 중· Renal Cell CarcinomaA Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
리드: 머크(MSD)
- 3상모집 중· Human Immunodeficiency Virus (HIV)A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
리드: 머크(MSD)
- 3상모집 중· Non-small Cell Lung CancerStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
협력: 머크(MSD)
- 3상모집 중· Non-small Cell Lung CancerA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
리드: 머크(MSD)
- 3상모집 중· Human Immunodeficiency Virus (HIV)A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
리드: 머크(MSD)
- 3상모집 중· Breast NeoplasmsA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
리드: 머크(MSD)
- 3상모집 중· Colon AdenocarcinomaA Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
리드: 머크(MSD)
- 3상모집 중· Breast NeoplasmsA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
리드: 머크(MSD)
- 3상모집 중· Oligometastatic Squamous Cell Carcinoma of the Head and NeckPembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
협력: 머크(MSD)
- 3상모집 중· Prostate CancerA Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
리드: 머크(MSD)
- 3상모집 중· Esophageal Squamous Cell CarcinomaA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
협력: 머크(MSD)
- 3상모집 중· Diffuse Large B-Cell LymphomaA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
리드: 머크(MSD)
- 3상모집 중· Coronavirus Disease (COVID-19)A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
리드: 머크(MSD)
- 3상모집 중· Carcinoma, Non-Small-Cell LungA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
리드: 머크(MSD) · 협력: 모더나
- 3상모집 중· Triple Negative Breast CancerNeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
협력: 길리어드, 머크(MSD)
- 3상모집 중· Cytomegalovirus InfectionsLetermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
협력: 머크(MSD)
- 3상모집 중· Triple-Negative Breast CancerSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
리드: 머크(MSD)
- 3상모집 중· Non-small Cell Lung CancerPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
리드: 머크(MSD)
- 3상모집 중· Neuromuscular BlocksSugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial
협력: 머크(MSD)
- 3상모집 중· Thrombocythemia, EssentialA Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
리드: 머크(MSD)
- 3상모집 중· Small Cell Lung CancerA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
협력: 머크(MSD)
- 3상모집 중· Prostate Cancer MetastaticStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
리드: 머크(MSD)
- 3상모집 중· Metastatic Castration-resistant Prostate Cancer (mCRPC)A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
리드: 머크(MSD)
- 3상모집 중· Non-small Cell Lung CancerA Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
리드: 머크(MSD) · 협력: 모더나
- 3상모집 중· Leukemia, Lymphocytic, Chronic, B-CellA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
리드: 머크(MSD)
- 3상모집 중· Pulmonary Arterial HypertensionA Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
리드: 머크(MSD)
- 3상모집 중· Bladder CancerAlvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
협력: 머크(MSD)
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.